Genentech is once again being accused of shortchanging providers in the amount of Herceptin, a breast-cancer drug, that it provides them, reports STAT, a unit of The Boston Globe.
Genentech, a unit of Roche, has been accused in lawsuits of cheating hospitals by placing less of the medication in vials than is appropriate, or misrepresenting the amount of the drug that must be mixed in a solution.